Translational & Cross-Reactive Studies with Prisys’ NHP Models of Immunology & Inflammation

Prisys Biotechnologies is at the forefront of advancing drug research and development through our innovative and comprehensive non-human primate (NHP) models for immunological and inflammatory diseases. With a robust and stable preclinical platform, we specialize in transforming drug R&D for various immunology and inflammation (I&I) indications, focusing particularly on rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory bowel disease (IBD).

WHY using NHP for I&I Research?

Using NHP models for I&I research provides several advantages, including the ability to study human biomarkers, clinical endpoints, and chronic biosamples, ensuring the translatability of dosages and true efficacy. These models also offer comprehensive safety-pharmacology assessments and evaluate ten key immunocytes (Neutrophils, Basophils, B Cells, CD8+ T Cells, CD4+ T Cells, CD4+/CD8+ T Cells, pDCs, NK Cells, Classical Monocytes, and Nonclassical Monocytes). A study by Nolan GP et al. (2022) highlights the effectiveness of NHP models, while a CT scan of acute phase lung inflammation in an NHP model of pneumonia, detected under a human CT sequence, confirms data translation (PRISYS, unpublished data, 2023).

Comprehensive I&I Models

Our NHP models are meticulously designed to replicate the complexities of human immune responses and inflammatory conditions. The Prisys' I&I models encompass a wide range of disease-specific and organ-specific inflammation studies, offering an invaluable tool for researchers aiming to understand and combat these conditions.

• Rheumatoid Arthritis (RA): Our rheumatoid arthritis (RA) model replicates the critical pathological features of human RA. This includes joint cavity shrinking, loss of growth plate, damage to articular cartilage and meniscus, and bone erosion. These characteristics make our model highly relevant for studying the disease's progression and evaluating the efficacy of new therapeutic agents.

• Psoriasis Model: Our psoriasis model effectively replicates the pathological findings observed in human psoriasis. After a 14-day IMQ challenge, the skin exhibits several key characteristics: necrotic tissue outside the epidermis, uneven epidermis thickness, local incomplete keratosis, and a decrease in collagen composition across the epidermis and dermis. Additionally, there is significant lymphocyte infiltration, mirroring the inflammatory response seen in human psoriasis. This model is invaluable for studying the pathophysiology of psoriasis and evaluating potential therapeutic interventions.

• Multiple Sclerosis (MS): Our MS models mimic the chronic inflammatory demyelination characteristic of the disease, facilitating the assessment of novel treatments targeting neuroinflammation and neuroprotection.
• Inflammatory Bowel Disease (IBD): Our IBD models enable the study of chronic intestinal inflammation, essential for developing new therapies aimed at treating Crohn's disease and ulcerative colitis.

Prisys Biotechnologies offers a comprehensive suite of NHP models for various immunological and inflammatory diseases. These include models for autoimmune conditions like Type I Diabetes, neuroinflammation in Multiple Sclerosis, and neurodegeneration in Parkinson’s Disease. Our inflammatory models cover Inflammatory Bowel Disease, Pruritus, Endotoxemia, and inflammation in lung, liver, and renal tissues. We also specialize in models for BSL-2 bacterial infections and allergic conditions such as Asthma, Atopic Dermatitis, and generalized allergies. Additionally, our models support immunogenicity studies focusing on T-cell-dependent responses, delayed-type hypersensitivity, and immunosuppression. We offer co-development plans for conditions like Sj?gren’s syndrome, Systemic Lupus Erythematosus, and IgA Nephropathy. Lastly, our Myasthenia Gravis model provides insights into this chronic autoimmune neuromuscular disease.

Supporting Different Drug Modalities

Prisys Biotechnologies excels in supporting various drug modalities, with extensive experience in transforming modalities from small molecules to biologics. Our track record includes successful assessments of antibodies, gene therapies, and other innovative treatments. Our expertise ensures that your drug development process is backed by reliable preclinical data, enhancing the likelihood of clinical success.

Clinical Transformation Capabilities

To facilitate the clinical translation of your research, we offer flexible in vivo imaging and bio-sampling plans. These capabilities allow for the accurate tracking of acute and chronic immune and disease changes, providing a comprehensive understanding of the therapeutic impact over time.

Advanced Immunology Assays

Our advanced immunology assays for NHPs include comprehensive blood immunoglobulin (IG) profiles, immunocyte panels, and cytokine analysis. These assays are essential for evaluating immune responses and the efficacy of immunomodulatory therapies, ensuring that you receive detailed and actionable data for your research.

Partner with Prisys for Cutting-Edge Research

By partnering with Prisys Biotechnologies, you gain access to a state-of-the-art preclinical platform that can significantly advance your immunological and inflammatory disease research. Our dedicated team is ready to collaborate with you, providing the expertise and resources necessary to drive your projects forward. To learn more about our comprehensive I&I platform and how it can benefit your research, please find attached our detailed descriptive materials. For more information on our NHP models or to arrange an introductory session, please contact us. We look forward to discussing how Prisys can support your drug R&D transformation and assist in your journey towards innovative therapeutic solutions.

Contact Us:

Prisys Biotech

[email protected]